Skip to content
Search

Latest Stories

DHSC grants price concessions for July

The Department of Health and Social Care (DHSC) have granted following price concessions for July 2021.

DrugPack sizePrice Concession
Baclofen 10mg tablets84£3.30
Loratadine 5mg/5ml oral solution100ml£7.75
Mebeverine 135mg tablets100£4.40
Pregabalin 100mg capsules84£5.42
Tolbutamide 500mg tablets28£16.79
Trimethoprim 50mg/5ml oral suspension sugar free100ml£11.94
Ursodeoxycholic acid 250mg capsules60£11.98

The Pharmaceutical Services Negotiating Committee had also released the list of Department of Health and Social Care-granted price concessions for July 2021 on July 14.


DrugPack sizePrice Concession
Eplerenone 25mg tablets28£11.95
Eplerenone 50mg tablets28£15.53
Etoricoxib 60mg tablets28£6.00
Etoricoxib 90mg tablets28£8.35
Naftidrofuryl 100mg capsules84£7.84
Olmesartan medoxomil 20mg tablets28£6.44
Olmesartan medoxomil 40mg tablets28£10.35
Pregabalin 75mg capsules56£4.18
Sodium fluoride 0.05% mouthwash sugar free250ml£1.74
Sulfasalazine 500mg gastro-resistant tablets112£17.52
Sulfasalazine 500mg tablets112£16.50

Please note that a price concession only applies for the month in which it is granted.

No additional prescription endorsement are required as the new price is automatically applied by the NHSBSA to all items submitted for payment in the same month for which a price concession is granted.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less